Effectiveness and safety of colistin: prospective comparative cohort study

Paul, Mical; Bishara, Jihad; Levcovich, Ariela; Chowers, Michal; Goldberg, Elad; Singer, Pierre; Lev, Shaul; Leon, Perla; Raskin, Maria; Yahav, Dafna; Leibovici, Leonard

doi:10.1093/jac/dkq069

Cited by 141 publications

(99 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(28) Only two classes of drugs, polymyxins and glycylcyclines have shown to have good in vitro activity against NDM-1 producers. (29) This may further lead us to reconsider the potential role of gene mutations in Class 1 integrons that may be involved in developing multi-drug resistance or even extremely drug resistant bacterial strains.…”

Section: Introductionmentioning

confidence: 99%

Emergence of Potential Superbug Mycobacterium Tuberculosis , Lessons from New Delhi Mutant-1 Bacterial Strains

Nazir

Abraham

Islam

2012

IJHS

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Emergence of Potential Superbug Mycobacterium Tuberculosis , Lessons from New Delhi Mutant-1 Bacterial Strains

Nazir

Abraham

Islam

2012

IJHS

View full text Add to dashboard Cite

show abstract

“…46,48,144 If the underlying problem is the spread of resistant clones of bacterial among the patients in a unit, the best answer is the reinforcement of infection control, not the use of more exotic and complex antimicrobial chemotherapy. Antimicrobial stewardship, aiming to minimize unnecessary broad spectrum antibiotic use and its associated collateral damage and resistance selection is likewise crucial in the present era of growing resistance.…”

Section: Discussionmentioning

confidence: 99%

“…Although several studies have presented case series with positive outcomes, treatment with colistin was associated with increased mortality as compared with other appropriate regimens in one retrospective study including a small number of onco-hematological patients. 46 In another retrospective study, summarizing the efficacy of colistin in the treatment of infections due to MDR Gram-negative bacteria, multivariate analysis showed that presence of hematological disease, including malignancy, was itself associated with a decreased probability of survival. 3 Two retrospective analyses that included patients with (mainly hematological) malignancies who were treated with colistin for MDR P. aeruginosa infections obtained differing results.…”

Section: Polymyxinsmentioning

confidence: 99%

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

et al. 2013

View full text Add to dashboard Cite

The detection of multi-resistant bacterial pathogens, particularly those to carbapenemases, in leukemic and stem cell transplant patients forces the use of old or non-conventional agents as the only remaining treatment options. These include colistin/polymyxin B, tigecycline, fosfomycin and various anti-gram-positive agents. Data on the use of these agents in leukemic patients are scanty, with only linezolid subjected to formal trials. The Expert Group of the 4 th European Conference on Infections in Leukemia has developed guidelines for their use in these patient populations. Targeted therapy should be based on (i) in vitro susceptibility data, (ii) knowledge of the best treatment option against the particular species or phenotype of bacteria, (iii) pharmacokinetic/pharmacodynamic data, and (iv) careful assessment of the risk-benefit balance. For infections due to resistant Gram-negative bacteria, these agents should be preferably used in combination with other agents that remain active in vitro, because of suboptimal efficacy (e.g., tigecycline) and the risk of emergent resistance (e.g., fosfomycin). The paucity of new antibacterial drugs in the near future should lead us to limit the use of these drugs to situations where no alternative exists. ABSTRACT © F e r r a t a S t o r t i F o u n d a t i o n 2 0 1 3organizing committee and experts were solicited to form the working group. The group reviewed the published English-language literature and prepared proposals on treatment options for infections due to resistant bacteria. Papers for review were sought using PubMed with the terms "linezolid", "daptomycin", "quinupristin/ dalfopristin", "colistin or polymyxin", "tigecycline", "fosfomycin", "telavancin", "ceftaroline" AND "stem cell transplantation or bone marrow transplant or leukemia or hematological malignancy or cancer". References cited in the articles identified were also considered. In respect of 'Duration of therapy', the main search terms used were "antibiotic therapy"; "stem cell transplantation or bone marrow transplantation or hematological malignancy or cancer"; "febrile neutropenia" and "duration therapy", "discontinuation antibiotics" and "microbiologically documented infection". Definitions of resistanceA bacterial isolate was considered non-susceptible if it was categorized resistant, intermediate or non-susceptible when using clinical breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST), Clinical and Laboratory Standards Institute (CLSI) or the US Food and Drug Administration (FDA). Definitions of 'MDR' vary among authors and usually presume resistance to at least two antibiotics used in empiric therapy (3 rd 4 th -generation cephalosporins, carbapenems or piperacillin/tazobactam) or resistance to at least three of the following antibiotic classes: antipseudomonal penicillins, cephalosporins, carbapenems, aminoglycosides and fluoroquinolones. [11][12][13][14][15] According to the recent definition of the European Centre for Disease Prevention and Control...

show abstract

“…Several retrospective studies have investigated β-lactam antibiotics (30). It's reported that polymyxin B treatment in the currently recommended dosage may be inferior to other drugs in the treatment of ventilatorassociated pneumonia (VAP) and tracheobronchitis caused by organisms tested as susceptible in vitro to this agent (29).…”

Section: Monotherapymentioning

confidence: 99%

Intravenous polymyxins: Revival with puzzle

Fei

et al. 2017

BST

View full text Add to dashboard Cite

Effectiveness and safety of colistin: prospective comparative cohort study

Abstract: The need for colistin treatment is associated with poorer survival. Adjusted analyses suggest that colistin is less effective and more toxic than beta-lactam antibiotics.

Cited by 141 publications

References 27 publications

Emergence of Potential Superbug Mycobacterium Tuberculosis , Lessons from New Delhi Mutant-1 Bacterial Strains

Emergence of Potential Superbug Mycobacterium Tuberculosis , Lessons from New Delhi Mutant-1 Bacterial Strains

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

Intravenous polymyxins: Revival with puzzle

Contact Info

Product

Resources

About